FDA Approvals and Treatment Advancements for Lung Cancer

On the heels of two FDA approvals in lung cancer treatments, what innovations are next?

The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 gene fusion.

An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung cancer.

The FDA has approved Imfinzi for some adults with limited-stage small cell lung cancer.